Horton S, Jones AP, Guly CM, et al. - Among children with juvenile idiopathic arthritis-associated uveitis (JIA-U) uncontrolled on methotrexate, researchers ascertained longer-term results of candidates recruited from a single center in the SYCAMORE trial, a randomized placebo-controlled trial of adalimumab vs placebo. For this investigation, they reviewed records of all 28 SYCAMORE candidates selected at the Bristol Eye Hospital at nearly 3-monthly intervals up to 5 years from the trial randomization date. After 1-2 years of treatment, drug-induced remission of JIA-U did not persist when adalimumab was withdrawn. According to this retrospective interventional case series, adalimumab has been well-tolerated and the outcomes of visual acuity have been outstanding.